Pharmacokinetics of antiretroviral regimens containing tenofovir disoproxil fumarate and atazanavir-ritonavir in adolescents and young adults with human immunodeficiency virus infection.
about
Low body weight in females is a risk factor for increased tenofovir exposure and drug-related adverse eventsImpact of small body weight on tenofovir-associated renal dysfunction in HIV-infected patients: a retrospective cohort study of Japanese patients.Personalized therapeutics: HIV treatment in adolescentsHIV protective efficacy and correlates of tenofovir blood concentrations in a clinical trial of PrEP for HIV prevention.Renal function declines more in tenofovir- than abacavir-based antiretroviral therapy in low-body weight treatment-naïve patients with HIV infection.Renal function in HIV-infected children and adolescents treated with tenofovir disoproxil fumarate and protease inhibitorsClinical evaluation of a dried blood spot assay for atazanavirPharmacological considerations for tenofovir and emtricitabine to prevent HIV infectionPlasma and intracellular tenofovir pharmacokinetics in the neonate (ANRS 12109 trial, step 2)Atazanavir/ritonavir-based combination antiretroviral therapy for treatment of HIV-1 infection in adults.Long-term safety and efficacy of atazanavir-based therapy in HIV-infected infants, children and adolescents: the Pediatric AIDS Clinical Trials Group Protocol 1020ASteady-state pharmacokinetics of tenofovir-based regimens in HIV-infected pediatric patients.Concentrations of tenofovir and emtricitabine in saliva: implications for preexposure prophylaxis of oral HIV acquisition.Plasma and intracellular population pharmacokinetic analysis of tenofovir in HIV-1-infected patients.Vitamin D3 decreases parathyroid hormone in HIV-infected youth being treated with tenofovir: a randomized, placebo-controlled trial.Ethical Issues in Adolescents' Sexual and Reproductive Health Research in NigeriaBeyond informed consent: ethical considerations in the design and implementation of sexual and reproductive health research among adolescents.Pharmacotherapy of pediatric HIV infectionTenofovir, emtricitabine, and tenofovir diphosphate in dried blood spots for determining recent and cumulative drug exposure.Age-related differences in plasma and intracellular tenofovir concentrations in HIV-1-infected children, adolescents and adultsEmtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men.Low atazanavir concentrations in cerebrospinal fluidAssociation of higher plasma vitamin D binding protein and lower free calcitriol levels with tenofovir disoproxil fumarate use and plasma and intracellular tenofovir pharmacokinetics: cause of a functional vitamin D deficiency?Intimate Partner Violence and Adherence to HIV Pre-exposure Prophylaxis (PrEP) in African Women in HIV Serodiscordant Relationships: A Prospective Cohort Study.Common clinical conditions - age, low BMI, ritonavir use, mild renal impairment - affect tenofovir pharmacokinetics in a large cohort of HIV-infected women.Pharmacokinetic optimization of antiretroviral therapy in children and adolescents.Emtricitabine/tenofovir in the treatment of HIV infection: current PK/PD evaluation.Steady-state pharmacokinetics of tenofovir disoproxil fumarate in human immunodeficiency virus-infected Chinese patients.Does Adherence Change When No One is Looking? Comparing Announced and Unannounced Tenofovir Levels in a PrEP Trial.Genetic Polymorphisms Affecting the Pharmacokinetics of Antiretroviral Drugs.Unboosted atazanavir for treatment of HIV infection: rationale and recommendations for use.Evaluating the association of single-nucleotide polymorphisms with tenofovir exposure in a diverse prospective cohort of women living with HIV.Evaluation of a Multidrug Assay for Monitoring Adherence to a Regimen for HIV Preexposure Prophylaxis in a Clinical Study, HIV Prevention Trials Network 073.Highly active antiretroviral therapy dysregulates proliferation and differentiation of human pre-adipocytes.PharmGKB summary: atazanavir pathway, pharmacokinetics/pharmacodynamics
P2860
Q28535587-ECE0C3D3-5212-40FD-B16B-473D097C6804Q31028855-62CFB92A-7E30-46C0-86DF-5C309AC3F50EQ33576926-444F68B5-8C72-4075-9E53-93BE62A2EA05Q33763000-DDE8A79F-A69D-4B33-B6B2-85C121879281Q34126724-450BB0B4-4944-4D40-A514-1B54023ACB3DQ34136166-02F2FC5E-5AD3-4C77-BF41-49E56D677668Q34150893-74A8570D-ECCC-4732-BEF0-9DD8775D7AFFQ34481359-77A5C1E7-3A33-4FE9-BEB9-00E652207130Q35005051-866662C7-2E69-47DB-B24A-B17EC4639AE6Q35079510-BBFDB427-A352-4004-96D7-21B9513AB0DAQ35163596-7572AEC4-95D6-4F01-A226-F3DE1F5AD35CQ35191539-10969979-00E8-453D-BF41-3E6D4E030074Q35270776-AC346C8D-E3B1-4C2A-9A7F-4F5C7F54B0F1Q35363649-4F04B02A-63A2-435A-A6CC-C2ED07856BE1Q35815286-357AEE49-FD71-4781-B0E3-31D222ADF8F4Q36143301-7D6BC78B-1B46-47CF-916B-E3809525735DQ36297699-CE176113-EBBF-444D-B343-FAFC5AEFE52FQ36301325-DDD40904-5B6A-499C-8456-D51FB5CABD1DQ36554980-8A7B833F-D466-4B7A-90F3-EFC525D14CC1Q36650454-C92DE659-5009-4F44-89E1-94C2EB63C3F4Q37042094-B25B7045-756E-4004-B168-942A9EA19A32Q37097831-E6BB3B84-E58C-42B9-87F6-7C765E50711FQ37263395-4163499C-EE36-498D-8518-A0D8D7EBA61AQ37341579-E26F8245-5F40-405A-9101-48BA259B8587Q37641171-A3C4EACE-D9F0-40D6-93AF-EF69008F083CQ37835819-15083F1F-30D5-4B3D-82B4-15D2F6314658Q38040137-5AD3D1CB-64C0-47F5-9FC0-C6DF6990D03FQ38798813-5D7F3671-6493-4A4F-B62A-09F09C0F0021Q38852658-F1820732-45E4-4FD6-89D6-5413A495B643Q38957969-4D6EB151-5BD8-495D-9DF4-83400A7B057EQ39007008-74CECD20-EB38-4A90-AC12-56995F1E92D7Q40219167-D345B33F-114A-427B-80F1-82C55C77B336Q40239354-F1B6050C-231A-4644-BA7D-B0FFE3F15479Q41450474-229D4CDE-D173-45CC-AA20-8EBFDBEC39E0Q57403878-39832A4F-1B74-4D81-8AE7-1C5BA5B6F4D6
P2860
Pharmacokinetics of antiretroviral regimens containing tenofovir disoproxil fumarate and atazanavir-ritonavir in adolescents and young adults with human immunodeficiency virus infection.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh
2007年學術文章
@zh-hant
name
Pharmacokinetics of antiretrov ...... unodeficiency virus infection.
@ast
Pharmacokinetics of antiretrov ...... unodeficiency virus infection.
@en
type
label
Pharmacokinetics of antiretrov ...... unodeficiency virus infection.
@ast
Pharmacokinetics of antiretrov ...... unodeficiency virus infection.
@en
prefLabel
Pharmacokinetics of antiretrov ...... unodeficiency virus infection.
@ast
Pharmacokinetics of antiretrov ...... unodeficiency virus infection.
@en
P2093
P2860
P356
P1476
Pharmacokinetics of antiretrov ...... unodeficiency virus infection.
@en
P2093
Adolescent Trials Network for HIV/AIDS Interventions
Bill G Kapogiannis
Coleen K Cunningham
Courtney V Fletcher
Craig M Wilson
D Robert Harris
Hanna Major-Wilson
Jennifer J Kiser
Larry R Muenz
Nancy X Liu
P2860
P304
P356
10.1128/AAC.00761-07
P407
P577
2007-11-19T00:00:00Z